Exclusive Summary

• A PSMA/B7-H3 bispecific antibody-drug conjugate (BsADC) with First-in-class potential, currently in Phase 1 clinical trials in China.
• Innovative Mechanism: Synergistic dual-targeting effectively overcomes tumor heterogeneity and resistance driven by the downregulation of single-target expression.
• Preclinical Superiority: Demonstrates superior antitumor activity in prostate and NSCLC PDX models over the leading competitor DS-7300, achieving dramatic tumor regression at a lower dose (6mg/kg vs 12mg/kg).
• Advanced Technology: Features a proprietary stable/cleavable linker, site-specific conjugation, and a highly potent Topo1i payload with a strong bystander killing effect.
• Massive Market Potential: Targets the $2.9 billion metastatic castration-resistant prostate cancer (mCRPC) market and broad lung cancer indications, making it a highly attractive asset for global out-licensing.

Asset Materials

Contact Us for Full Materials